• Legend Biotech recently reported early Phase 1 data for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy in relapsed/refractory B-cell non-Hodgkin lymphoma, showing high response rates, dose-dependent in vivo CAR-T expansion, and a manageable safety profile without lymphodepleting chemotherapy.
• The ability of LB2501 to generate CAR-T cells directly inside patients from a single off-the-shelf infusion could materially simplify treatment logistics compared with traditional ex vivo CAR-T approaches.
• We will now explore how this early in vivo CAR-T success, particularly the strong responses at higher dosing, may influence Legend’s investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Legend Biotech Investment Narrative Recap

To own Legend Biotech, you need to believe CARVYKTI can fund a broader, de-risked cell therapy portfolio while losses narrow over time. The LB2501 in vivo CAR-T data strengthen the argument that Legend’s pipeline could eventually diversify revenue away from a single product, but they do not change the near term reality that CARVYKTI performance and ongoing R&D spend remain the key catalyst and the biggest risk.

Among recent updates, the first in human data for LB2102 in small cell lung cancer stand out beside LB2501. Together, they underline Legend’s push beyond multiple myeloma into both in vivo and solid tumor CAR-T, which could be important if CARVYKTI growth slows or competition intensifies. For now, though, these early programs are scientific, not financial, drivers.

Yet while LB2501’s early success is exciting, investors should also be aware that the company’s heavy reliance on CARVYKTI means...

Legend Biotech’s narrative projects $2.1 billion in revenue and $501.1 million in earnings by 2029.

Uncover how Legend Biotech's forecasts yield a $57.24 fair value, a 58% upside to its current price.

Exploring Other Perspectives

Some analysts were already assuming revenue could reach about US$2.7 billion and earnings about US$869.2 million by 2029, so this LB2501 update may push your view closer to those optimistic forecasts or keep you more cautious, depending on how you weigh early in vivo CAR T data against CARVYKTI concentration risk.

Explore 5 other fair value estimates on Legend Biotech - why the stock might be worth over 3x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Legend Biotech research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free Legend Biotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Legend Biotech's overall financial health at a glance.

Looking For Alternative Opportunities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.